Riliprubart vs IVIg for CIDP (VITALIZE Trial)
(VITALIZE Trial)
Trial Summary
What is the purpose of this trial?
This study compares the effectiveness of an investigational study drug, riliprubart, against standard IVIg treatment for the management of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). It is a Phase 3 study. Disclaimer: Intended for U.S. Audiences Only. ©2026 Sanofi US Services, Inc. All Rights Reserved. The investigational study drug is not approved by health authorities such as the US Food and Drug Administration (FDA) and is still under investigation, so its effectiveness and safety have not been established.
Timeline
Screening
Participants are evaluated to confirm eligibility
Study Treatment
Participants receive regular doses of either riliprubart (with placebo IVIg) or IVIg continuation (with placebo riliprubart).
Open-label Extension
All participants receive open-label riliprubart through Week 48.
Follow-up
Participants are monitored after completing treatment through two clinic visits and some phone calls.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sanofi
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.